Rabbit PELP1 Monoclonal Antibody | anti-PELP1 antibody

PELP1 (RBT-PELP1)

Cat. Num. AAA370510

• Reactivity: Human, Mouse, Rat
• Synonyms: PELP1; Monoclonal Antibody; PELP1 (RBT-PELP1); pelp; anti-pelp; hmx3; anti-hmx3; Proline-; glutamic acid- and leucine-rich protein 1; anti-PELP1 antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Monoclonal
• Isotype: IgG
• Clone Number: RBT-PELP1
• Form/Format: Paraffin, Frozen; PELP1 is a rabbit monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.

• Immunogen: Recombinant human PELP1 protein.
• Control: Placenta, Breast, Colon, Testis, Transitional Cell Carcinoma, T Cell Lymphoblastic Lymphoma, Seminoma
• Localization: Nuclear
• Preparation and Storage: Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)

Dilution Information

Immunohistochemistry (IHC)

(PELP1 Antibody Immunohistochemistry on an FFPE Ductal Breast Carcinoma Tissue)

Related Product Information for anti-PELP1 antibody

Proline-, glutamic acid- and leucine-rich protein 1 (PELP1) gene expresses PELP1, also known as HMX3 protein, a transcription factor that regulates the expression of many signaling proteins. PELP1 is mainly known as a coactivator for Estrogen Receptor activity, where it participates in complexes that facilitate transcription according to ER-mediated signals. PELP1 interacts with a variety of signaling proto-oncogenes such as Src, HER2, and EGFR, which are known to contribute to tumor formation, and with hormonal pathways that can contribute to hormonal therapy resistance. The wide range of signaling functions makes PELP1 susceptible to expression deregulation in hormone-centered cancers, particularly in Breast, Endometrial, Ovarian, and Prostate Tumors, as well as Ductal and Colorectal Carcinomas.
A study has found that PELP1 antibody expression rate was the highest in breast cancers (70.5%) among different cancers. Compared to GATA3, Mammaglobin and GCDFP-15, PELP1 was less sensitive than GATA3 for luminal cancers, but was the most sensitive for non-luminal cancers. PELP1 has low expression rate (< 20%) in Colorectal Cancers, Gastric Cancers and Renal Cell Carcinomas, but higher in Lung Cancers (49.1%) and Ovarian Cancers (42.3%). PELP1 expression was associated with poor outcome in non-luminal cancers and modified the prognostic effects of AR, suggesting the potential significance of NR co-regulator in prognostication. Another study found the overall value of the PELP1 H-score in Breast cancer was significantly higher than that in breast fibroadenoma (p<0.001) with Breast Cancer patients, the ER/HER-2-positive group having significantly higher PELP1 H-scores than their negative counterparts (p=0.003 for ER and p=0.022 for HER-2) and the Ki-67-high group also showed significantly higher PELP1 H-scores than the Ki-67-low group.